Aesthetic medical device company Syneron Candela has launched a new dual wavelength fractional modality for the PicoWay picosecond laser.
The Resolve fractional picosecond modality features both 532nm and 1064nm wavelengths. The device employs a holographic fractionator, which aims to deliver precise consistent energy to the entire treatment area. The two different wavelengths aim to allow treatment of shallow lesions, with the 532nm wavelength and deeper lesions with 1064nm.
"PicoWay continues to exceed expectations and delight customers,” said Amit Meridor, chief executive officer of Syneron Candela. “We are thrilled to introduce to the market the next step in the PicoWay story, Resolve, the fractional modality that uniquely includes two wavelengths. Our PicoWay customers know that we have a robust road map for PicoWay which includes expanded applications and new capabilities enabled by outstanding technology. It is energising to witness the excitement that this product is experiencing in the marketplace as we introduce appealing new ways to utilise the technology to treat patients."